CytoMed Therapeutics Net Income Over Time
| GDTC Stock | 1.02 0.07 7.37% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out CytoMed Therapeutics Performance and CytoMed Therapeutics Correlation. Will Biotechnology sector continue expanding? Could CytoMed diversify its offerings? Factors like these will boost the valuation of CytoMed Therapeutics. Market participants price CytoMed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CytoMed Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.25) | Revenue Per Share | Quarterly Revenue Growth 1.01 | Return On Assets | Return On Equity |
The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, CytoMed Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare CytoMed Therapeutics and related stocks such as Enlivex Therapeutics, MetaVia, and NuCana PLC Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ENLV | (229 K) | (229 K) | (229 K) | (1.1 M) | (7 M) | (15.4 M) | (16 M) | (5.9 M) | (4.9 M) | (9.4 M) | (11.8 M) | (14.5 M) | (31.1 M) | (29.1 M) | (15 M) | (13.5 M) | (14.2 M) |
| MTVA | (320 K) | (320 K) | (320 K) | (320 K) | (320 K) | (9 M) | (14.6 M) | (33.4 M) | (15.5 M) | (21.3 M) | (29.7 M) | (15.3 M) | (14 M) | (12.5 M) | (27.6 M) | (24.8 M) | (26.1 M) |
| NCNA | (6.2 K) | (6.2 K) | (6.2 K) | (6.2 K) | (6.2 K) | (5.3 M) | (6 M) | (23.1 M) | (13.8 M) | (21.4 M) | (30.7 M) | (40.5 M) | (32 M) | (27.6 M) | (19 M) | (17.1 M) | (18 M) |
| NRSN | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (2.8 M) | (4 M) | (12.3 M) | (10.1 M) | (10.2 M) | (9.2 M) | (9.6 M) |
| LSTA | (2.7 M) | (47.1 M) | (54.8 M) | (39 M) | (54.9 M) | (80.9 M) | (32.7 M) | 23 M | (16.2 M) | (20.1 M) | (8.2 M) | (27.5 M) | (54.2 M) | (20.8 M) | (20 M) | (18 M) | (18.9 M) |
| CLGN | (4.5 M) | (4.5 M) | (4.5 M) | (4.6 M) | (3.6 M) | (4.8 M) | (7.3 M) | (5.8 M) | (6.2 M) | (11.2 M) | (5.8 M) | 237 K | (16.9 M) | (7 M) | (16.6 M) | (14.9 M) | (14.2 M) |
| NRXS | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3.7 M) | (3 M) | (4.8 M) | (14.6 M) | (8.2 M) | (7.4 M) | (7.8 M) |
| PASG | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (45.6 M) | (112.2 M) | (185.4 M) | (136.1 M) | (102.1 M) | (64.8 M) | (58.3 M) | (61.2 M) |
| XCUR | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (16.9 M) | (11 M) | (22.4 M) | (26.3 M) | (24.7 M) | (64.1 M) | (2.6 M) | (16.9 M) | (9.7 M) | (8.7 M) | (9.2 M) |
CytoMed Therapeutics and related stocks such as Enlivex Therapeutics, MetaVia, and NuCana PLC Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in CytoMed Therapeutics financial statement analysis. It represents the amount of money remaining after all of CytoMed Therapeutics Limited operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| CytoMed Therapeutics Limited | GDTC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1 Commonwealth Lane, |
| Exchange | NASDAQ Exchange |
null 1.02
Check out CytoMed Therapeutics Performance and CytoMed Therapeutics Correlation. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
CytoMed Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.